Melbourne-based early stage medical technology company 4Dx has announced the appointment of Ms Zita Peach as a Non-Executive Director.
Ms Peach, who has more than 20 years of pharmaceutical, biotechnology and medical device experience, will join the 4Dx executive team as they work towards commercialising their four-dimensional lung imaging technology - 4DxV.
DxV is four-dimensional X-ray imaging technology that provides detailed maps of regional lung motion and airflow in real-time within the breathing lungs.
Ms Peach’s previous executive roles include Executive Vice President for South Asia Pacific and Managing Director of Australia and New Zealand for Fresenius Kabi, a leading global healthcare company in the hospital market. She has also worked for major pharmaceutical companies CSL and Merck Sharp & Dohme, and currently holds Non-Executive Directorships with Vision Eye Institute and Starpharma.
At CSL, Ms Peach was Vice President of Business Development, where she oversaw the commercialisation of the company's extensive early stage R&D portfolio and licensing agreements. She was also involved in the international expansion of CSL's influenza vaccine.
Founder and Executive Chairman of 4Dx, Andreas Fouras, said: “As an early stage medical technology company, we’re delighted to have someone as experienced as Zita come on board.“
“Zita brings proven commercial experience and global business development skills at a time when we’re working towards clinical validation and expanding within the US market," he added.
Ms Peach said she was looking forward to working with 4Dx’s executive team and the broader medical community to help develop a clear commercial pathway for 4Dx’s ground-breaking technology.